Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Amortization of Deferred Charges (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $99849.0 as the latest value for Q2 2020.

  • On a quarterly basis, Amortization of Deferred Charges fell 76.17% to $99849.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $235636.0, a 83.52% decrease, with the full-year FY2024 number at $2.7 million, up 6.01% from a year prior.
  • Amortization of Deferred Charges was $99849.0 for Q2 2020 at Outlook Therapeutics, down from $120065.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.7 million in Q3 2017 to a low of $2504.0 in Q2 2016.
  • A 5-year average of $405344.2 and a median of $230217.0 in 2018 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 53110.98% in 2017, then plummeted 96.51% in 2019.
  • Outlook Therapeutics' Amortization of Deferred Charges stood at $140820.0 in 2016, then surged by 311.58% to $579586.0 in 2017, then decreased by 22.29% to $450381.0 in 2018, then tumbled by 96.51% to $15722.0 in 2019, then soared by 535.09% to $99849.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Amortization of Deferred Charges are $99849.0 (Q2 2020), $120065.0 (Q1 2020), and $15722.0 (Q4 2019).